The development of novel bio(techno)logical drugs, mainly consisting in antibodies, can significantly exploit molecular modeling tools to successfully accelerate discovery. In my presentation, I will introduce participants to the most up-to-date antibody modeling techniques with specific applications aimed at predicting their interaction with antigens, and mutagenesis for their optimization.
Beyond small molecules: Protein-Protein Interfaces & Biotech Drugs / I. Eberini. ((Intervento presentato al convegno Training and innovation course in drug design tenutosi a Milano nel 2017.
Beyond small molecules: Protein-Protein Interfaces & Biotech Drugs
I. EberiniPrimo
2017
Abstract
The development of novel bio(techno)logical drugs, mainly consisting in antibodies, can significantly exploit molecular modeling tools to successfully accelerate discovery. In my presentation, I will introduce participants to the most up-to-date antibody modeling techniques with specific applications aimed at predicting their interaction with antigens, and mutagenesis for their optimization.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.